The rats in the DBI + fingolimod group (n = 42) were intraperitoneally injected with 0.5 mg/kg body weight fingolimod (dissolved in 0.9% sodium chloride; Cayman Chemical, 10006292) daily for 3 consecutive days beginning 30 min after the DBI procedure according to prior research and our initial results.
32 (link) The rats in the sham (n = 42) and DBI groups (n = 42) were injected with equivalent amounts of 0.9% sodium chloride.
TGN‐020 is known to inhibit the expression of AQP4 M23, which leads to the disruption of astrocytic AQP4 polarization.
33 (link) In the DBI + fingolimod + TGN‐020 group (n = 18), before fingolimod was administered, TGN‐020 was used to pharmacologically inhibit AQP4 polarity as previously described.
34 (link)
32 (link) The rats in the sham (n = 42) and DBI groups (n = 42) were injected with equivalent amounts of 0.9% sodium chloride.
TGN‐020 is known to inhibit the expression of AQP4 M23, which leads to the disruption of astrocytic AQP4 polarization.
33 (link) In the DBI + fingolimod + TGN‐020 group (n = 18), before fingolimod was administered, TGN‐020 was used to pharmacologically inhibit AQP4 polarity as previously described.
34 (link)
Free full text: Click here
